Researchers at the Casey Eye Institute, Oregon Health & Science University (OHSU), Portland, USA, have provided formal results of a Phase 1/2 study, published at… Read More »A phase 1/2 multi-centre study provides results for the treatment of XLRP, promising a Phase 2/3 study to progress in 2025.
Researchers at the Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea, have outlined an increasing future burden of depressive disorders, providing… Read More »An investigation of the association between Retinitis pigmentosa (RP) and depressive disorder, including a call for practical training and methods.
Clinical researchers at the Department of Ophthalmology, Bascom Palmer Eye Institute, in the University of Miami, Florida, have presented an update on clinical trial endpoints… Read More »An update of clinical trial endpoints provide a dynamic trial environment across a range of inherited retinal degenerations (IRDs).
Clinical researchers at the Center for Hereditary Retinal Degenerations, Scheie Eye Institute, University of Pennsylvania, Philadelphia, have published the results of a Phase 1/2 study… Read More »Dose escalation study of ASTN-101 (AAV5-GUCY2D) for LCA1 patients provide improvement in FST and BCVA (Phase 1/2).
An international clinical research consortium has reported recommendations on endpoints and design of clinical trials in USH2A-related retinal degenerations. The study, supported by the US… Read More »Endpoints and clinical trial design for IRDs and USH2A reporting outcomes from a natural history study.
EURETINA Congress, Barcelona – Sept. 20th, 2024: Prof. M. Dominick Fischer, based at Nuffield Laboratory of Ophthalmology, University of Oxford and the Oxford Eye Hospital,… Read More »Real world data from the treatment by voretigene neparvovec (Luxturna) of LCA2-RPE65 patients across 24 countries.
Researchers at Nuffield Laboratory of Ophthalmology, University of Oxford and the Oxford Eye Hospital, NHS Foundation Trust, has reported that a surrogate biomarker (comprising the… Read More »Clinical trial endpoints use EZ and ELM biomarkers for selecting patients for treatments on X-linker retinitis pigmentosa.
Researchers at the Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy and the Department of Ophthalmology, University of Oslo, Norway, have published a… Read More »A systematic review of retinitis pigmentosa and its therapeutic approaches report different treatments and disorders.
An international consortium of researchers on a multi-centre study on congenital stationary night blindness (CSNB), led by Oregon Health and Science University Casey Eye Institute,… Read More »An international multi-centre study on congenital stationary night blindness (CSNB) report several genetic variants on myopia.
Researchers at Janssen Pharmaceuticals N.V. and the ERN-EYE Network at the Center for Retinitis Pigmentosa of Veneto Region, Camposampiero Hospital, Padua, Italy, have reported results… Read More »Results from a cross sectional study of XLRP patients suggest that several healthcare systems require early diagnosis and effective management of patients.
